陈适 , 刘田 . 重视系统性血管炎的早期识别和个体化治疗[J]. 北京大学学报（医学版）, 2022 , 54(6) : 1065 -1067 . DOI: 10.19723/j.issn.1671-167X.2022.06.001
| 1 | Kitching AR , Anders HJ , Basu N , et al. ANCA-associated vasculitis[J]. Nat Rev Dis Primers, 2020, 6 (1): 71. |
| 2 | Aladdin JM . An update on the epidemiology of ANCA-associated vasculitis[J]. Rheumatology (Oxford), 2020, 59 (Suppl 3): 42- 50. |
| 3 | Gary SF , Ralph CB , Sherine EG , et al. Kelley & Firestein's textbook of rheumatology[M]. 11th. Philadelphia: Elsevier, 2020: 1485. |
| 4 | 余洁, 陈适, 栗占国. 抗中性粒细胞胞浆抗体阳性患者疾病谱分析[J]. 中华全科医师杂志, 2010, 9 (1): 26- 30. |
| 5 | 赵明辉. 抗中性粒细胞胞质抗体相关小血管炎诊断和治疗中的问题与对策[J]. 中华风湿病学杂志, 2009, 13 (4): 217- 219. |
| 6 | Buttgereit F , Dejaco C , Matteson EL , et al. Polymyalgia rheumatica and giant cell arteritis: A systematic review[J]. JAMA, 2016, 315 (22): 2442- 2458. |
| 7 | Yanaoka H , Nagafuchi Y , Hanata N , et al. Identifying the most influential gene expression profile in distinguishing ANCA-associated vasculitis from healthy controls[J]. J Autoimmun, 2021, 119 (5): 102617. |
| 8 | Chen Z , Zhao YY , Wang Q , et al. Imaging features of 18FFDG PET/CT in different types of systemic vasculitis[J]. Clin Rheumatol, 2022, 41 (5): 1499- 1509. |
| 9 | Robson JC , Grayson PC , Ponte C , et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis[J]. Ann Rheum Dis, 2022, 81 (3): 315- 320. |
| 10 | Suppiah R , Robson JC , Grayson PC , et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis[J]. ArthritisRheumatol, 2022, 74 (3): 400- 406. |
| 11 | Jones RB , Tervaert JW , Hauser T , et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis[J]. N Engl J Med, 2010, 363 (3): 211- 220. |
| 12 | Michael W , Peter AM , Chen AP , et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis[J]. N Engl J Med, 2020, 382 (7): 622- 631. |
| 13 | de Groot K , Rasmussen N , Bacon PA , et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis[J]. Arthritis Rheum, 2005, 52 (8): 2461- 2469. |
| 14 | Guillevin L , Pagnoux C , Karras A , et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis[J]. N Engl J Med, 2014, 371 (19): 1771- 1780. |
| 15 | Pagnoux C , Mahr A , Hamidou MA , et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis[J]. N Engl J Med, 2008, 359 (26): 2790- 2803. |
| 16 | Goglin S , Chung SA . New developments in treatments for systemic vasculitis[J]. Curr Opin Pharmacol, 2022, 66 (10): 102270. |
| 17 | Sharon AC , Carol AL , Mehrdad M , et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis[J]. Arthritis Care Res(Hoboken), 2021, 73 (8): 1088- 1105. |
| 18 | Michael EW , Praveen A , David J , et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis[J]. N Engl J Med, 2017, 376 (20): 1921- 1932. |
| 19 | David RJ , Peter AM , Thomas JS , et al. Avacopan for the treatment of ANCA-associated vasculitis[J]. N Engl J Med, 2021, 384 (7): 599- 609. |
| 20 | Maz M , Chung SA , Abril A , et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the management of giant cell arteritis and Takayasu arteritis[J]. Arthritis Rheumatol, 2021, 73 (8): 1349- 1365. |
| 21 | He J , Zhang R , Shao M , et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: A randomised, double-blind, placebo-controlled trial[J]. Ann Rheum Dis, 2020, 79 (1): 141- 149. |
| 22 | Michelle R , Roberta L , Patrice C , et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial[J]. Ann Rheum Dis, 2019, 78 (2): 209- 217. |
| 23 | Carol AL , David C , Steven RY , et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis[J]. Arthritis Rheumatol, 2017, 69 (4): 837- 845. |
| 24 | Nils V , Wolfgang AS , Peter L , et al. Efficacy and safety of secukinumab in patients with giant cell arteritis: Study protocol for a randomized, parallel group, double-blind, placebo-controlled phase Ⅱ trial[J]. Trials, 2021, 22 (1): 543. |
| 25 | Kong XF , Sun Y , Dai XJ , et al. Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: A prospective observational study[J]. Ann Rheum Dis, 2022, 81 (1): 117- 123. |
/
| 〈 |
|
〉 |
